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Abstract 
Background: Plasmodium vivax parasites are the predominant cause of malaria infections in the Brazilian Amazon. 
Infected individuals are treated with primaquine, which can induce haemolytic anaemia in glucose-6-phosphate 
dehydrogenase (G6PD)-deficient individuals and may lead to severe and fatal complications. This X-linked disorder 
is distributed globally and is caused by allelic variants with a geographical distribution that closely reflects popula-
tions exposed historically to endemic malaria. In Brazil, few studies have reported the frequency of G6PD deficiency 
(G6PDd) present in malaria-endemic areas. This is particularly important, as G6PDd screening is not currently per-
formed before primaquine treatment. The aim of this study was to determine the prevalence of G6PDd in the region 
of Alto do Juruá, in the Western Brazilian Amazon, an area characterized by a high prevalence of P. vivax infection.
Methods: Five-hundred and sixteen male volunteers were screened for G6PDd using the fluorescence spot test 
(Beutler test) and CareStart™ G6PD Biosensor system. Demographic and clinical-epidemiological data were acquired 
through an individual interview. To assess the genetic basis of G6PDd, 24 SNPs were genotyped using the Kompetitive 
Allele Specific PCR assay.
Results: Twenty-three (4.5%) individuals were G6PDd. No association was found between G6PDd and the number 
of malaria cases. An increased risk of reported haemolysis symptoms and blood transfusions was evident among the 
G6PDd individuals. Twenty-two individuals had the G6PDd A(−) variant and one the G6PD A(+) variant. The Medi-
terranean variant was not present. Apart from one polymorphism, almost all SNPs were monomorphic or with low 
frequencies (0–0.04%). No differences were detected among ethnic groups.
Conclusions: The data indicates that ~1/23 males from the Alto do Juruá could be G6PD deficient and at risk of 
haemolytic anaemia if treated with primaquine. G6PD A(−) is the most frequent deficiency allele in this population. 
These results concur with reported G6PDd in other regions in Brazil. Routine G6PDd screening to personalize pri-
maquine administration should be considered, particularly as complete treatment of patients with vivax malaria using 
chloroquine and primaquine, is crucial for malaria elimination.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) is an 
enzyme present in all cells and is involved in the preven-
tion of cellular oxidative damage. This enzyme has a par-
ticularly critical function to control the oxidative damage 
in red blood cells (RBC) and maintain their integrity. 
In spite of its vital function, the G6PD gene, located on 
chromosome X, has a high genetic diversity and is highly 
polymorphic. The majority of mutations do not alter the 
function of the enzyme, but some can lead to a decrease 
in the enzymatic activity and cause the G6PD deficiency 
(G6PDd) phenotype [1, 2].
G6PDd is very common worldwide and is character-
ized by a range of enzyme activity levels and associated 
phenotypes [3]. The majority of cases are asymptomatic 
but with a high risk of developing acute haemolytic anae-
mia with exposure to associated triggers. These triggers 
include fava bean consumption, oxidizing medications 
such as sulfonamides, nitrofurantoin and primaquine 
(PQ) treatment used to prevent Plasmodium vivax clini-
cal relapses [4].
Severe G6PDd symptoms, including chronic or inter-
mittent haemolytic anaemia, are in general associated 
with rare allelic variants. The geographical distribution of 
G6PDd globally is variable, but it is particularly prevalent 
in malaria-endemic countries [5, 6]. The highest frequen-
cies are reported in Africa and in a belt extending from 
the Mediterranean to Southeast Asia [6]. The frequencies 
vary from ~2 to 30%, depending on the country and eth-
nic group. In the Americas, G6PDd is less common, with 
frequencies ranging from 0 to ~14% [7].
Two genetic variants (G6PD A(−) and G6PD Medi-
terranean) are among the most frequent and are preva-
lent in particular populations [3, 6]. The A(−) genetic 
variant, which results from two non-synonymous muta-
tions (G202A/A376G) is common in individuals of sub-
Saharan African origin [3, 6]. This variant is in general 
characterized by an enzymatic activity higher than 10% 
of normal levels [8]. The G6PD Mediterranean vari-
ant (C563T) is predominant in West Asia (from Turkey, 
Saudi Arabia to India) [3, 6], and causes some of the most 
severely deficient phenotypes with <1% enzymatic activ-
ity [8]. In Southeast Asia, the prevalence of G6PDd var-
ies widely among regions and ethnic groups and several 
genetic variants are observed.
In Brazil, a predominance of the African variant (A−) 
has been reported, and few new mutations identified 
[7]. To date, there are few estimates of the frequency of 
G6PDd in malaria endemic areas. This is particularly 
important as P. vivax is the main malaria parasite in 
Brazil and PQ, which triggers acute haemolytic anae-
mia in G6PDd individuals, is the recommended drug to 
prevent P. vivax clinical relapses. Therefore, to predict 
the potential incidence of primaquine (PQ)-associated 
acute haemolytic anaemia and determine the likely need 
for G6PDd testing, this study aimed to estimate the 
prevalence of phenotypic G6PDd and identify the main 
genetic variants in a malaria-endemic area in the West-
ern Brazilian Amazon.
Methods
Study population and region
A cross-sectional study was carried out from June to 
August 2016 in the Amazonian region of the Alto do 
Juruá valley (Acre, Brazil). This region, which has high 
risk for malaria transmission, includes 5 main cities: Cru-
zeiro do Sul (7°37′51″S, 72°40′12″W), Rodrigues Alves 
(07°44′31″S, 72°38′49″W), Mâncio Lima (07°36′50″S, 
72°53′4″W), Marechal Thaumaturgo (08°56′27″S, 
72°47′31″W) and Porto Walter (08°16′08″S, 72°44′38″W), 
with a total population in 2010 of 131,505 inhabit-
ants (66,792 males) [9]. Participant volunteers were 
recruited by a media (radio, TV) campaign where they 
were encouraged to visit participating study clinics and 
schools in the Vale do Juruá region. A total of 653 men 
living in the Juruá Valley region agreed to participate in 
the study. After exclusions, a total of 516 male individuals 
from 18–90  years old were selected for analyses (Addi-
tional file  1). Demographic and clinical-epidemiological 
data such as ethnic origin (Afro-descendants, European 
descents, Mestizo (combined Brazilian native, with Euro-
pean and African ancestry), previous malaria infection 
and previous clinical complications, particularly anae-
mia, black urine and need for blood transfusion, were 
acquired through an individual interview. The data were 
recorded in a standard questionnaire applied by trained 
interviewers.
Evaluation of G6PD deficiency and malaria infection
Four ml of venous blood were collected from each per-
son using EDTA tubes (BD Vacutainer). The qualitative 
determination of G6PDd in whole blood was performed 
by a fluorescence spot test using the method of Beutler 
[10] and positive individuals were also tested with the 
CareStart™ G6PD Biosensor system (ACCESSBIO, INC) 
for a quantitative measurement by digital puncture. The 
reliability of the G6PD Biosensor was assessed by using a 
control strip provided prior to each testing. In addition, 
quantification of haemoglobin was performed using the 
 Hemocue® portable spectrophotometer for all volun-
teers. The result of the enzymatic activity was calculated 
by normalizing the value attained in the Carestart test 
(U/dl), which is linked to the value of the haemoglobin 
level measured by the Hemocue (g/dl). All tests were per-
formed immediately after blood collection. At the time of 
recruitment, for the volunteers who presented signs and/
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or symptoms of malaria, the diagnosis was made by thick 
blood smears and read by a local microscopist from the 
endemic surveillance team as recommended by the Bra-
zilian Ministry of Health. Only 14 individuals were posi-
tive. The fact these individuals had malaria at the time of 
recruitment was not an exclusion factor.
G6PD genotyping
For molecular characterization of G6PDd, total DNA 
was obtained from whole blood cells through the use of a 
commercially available extraction kit (QIAmp DNA Mini 
Kit, Qiagen), following the manufacturer’s instructions. A 
total of 24 single nucleotide polymorphisms (SNPs) were 
genotyped using the Kompetitive Allele Specific PCR 
(KASP) assay (LGC Genomics, UK).
SNP selection was based on polymorphisms associ-
ated with G6PDd. This included SNPs identified in stud-
ies performed in Brazil and Latin America, as well as 
reported by the 1000 Genomes project [7, 11–13]. For 
each putative SNP sequence, a KASP assay was designed, 
comprising two allele-specific forward primers, and one 
common reverse primer. Genotyping reactions were per-
formed using the IntelliQube (LGC, Douglas Scientific, 
USA) to complete all DNA arraying, sample and reagent 
dispensing, plate sealing and fluorescence detection steps 
for SNP genotyping. Reactions were performed in Array 
Tape with 384 reactions wells per array. To each well, 
0.8 μL of genomic DNA suspension was arrayed followed 
by dispensing 0.8  μL 2× KASP reaction mix with the 
non-contact dispense jet to create total reaction volumes 
of 1.6 μL. The final reaction volume of 1.6 µL contained 
1× KASP Array Tape Master mix (LGC Genomics, 
UK), 0.07 µL KASP assay mix and between 0.5 and 5 ng 
genomic DNA. Thermal cycling was performed using a 
Hydrocycler (LGC Genomics, UK). The following cycling 
conditions were used: 15  min at 94  °C; 10 touchdown 
cycles of 20 s at 94 °C, 60 s at either 63–57 °C or 68–62 °C 
(dropping 0.6 °C per cycle) depending on primer thermo-
dynamic profile; and amplification of 35 cycles of 20 s at 
94  °C, 60 s at 57  °C). Following completion of the PCR, 
each sample was assigned a genotype based on cluster 
plot analysis of raw data using Kraken software (LGC 
Genomics, UK).
Statistical analysis
The statistical analyses were performed using Stata ver-
sion 14.1 (STATA Corp, College Station, TX, USA). The 
prevalence of G6PDd and variants was calculated as pro-
portions with 95% CI (CI 95%). Qualitative data were 
analysed with the Chi square test or the Fisher Exact-
test when indicated. To assess the extent to which ethnic 
origin, previous malaria exposure and previous clinical 
complications were associated with G6PDd, odds ratios 
(OR) with CI 95% were estimated by univariate logis-
tic regression analysis. Adjustment for multiple vari-
ables was performed by adding the covariates in a set of 
multiple logistic-regression models. Test for trend was 
conducted through the Exact test for trend (modified 
Wilcoxon test). A two-tailed value of P < 0.05 was consid-
ered statistically significant.
Results
A total of 516 male volunteers from the Juruá Region in 
the state of Acre were screened for G6PD activity using 
the Beutler test. The majority of the individuals were of 
combined Mestizo (European-Amerindian-African) 
descent (74.6%), followed by European (14.1%) and Afro-
descendants (10.3%) (Table 1). Twenty-three individuals 
were identified has G6PDd (4.5%) and no difference was 
observed between ethnic groups (p =  0.877). For these 
individuals, the activity of the G6PD enzyme was meas-
ured using the CareStart™ G6PD Biosensor, which gives 
a quantitative measurement of total enzyme activity. 
The concordance of the two tests was 100%. The G6PD 
quantitative results were normalized using haemoglobin 
(Hb) levels, which were normal for all G6PDd individuals 
(>13 g/dL) (Additional file 2). The average G6PD activity 
was 4.3 U/gHb (IQR 3.4–4.9 U/gHb) (Additional file 2). 
The normal G6PD activity values can vary but according 
to WHO criteria, the mean normal activity is 16.37 U/g 
Hb, the upper limit of mild/partial deficiency is 9.82 U/g 
Hb and 1.64 is the upper limit of total deficiency. None of 
the G6PDd individuals in this study had total deficiency, 
but all had values lower than the mild/partial deficiency 
upper limit.
The clinical history of the volunteers was also inves-
tigated, particularly to verify if there is a correlation 
between G6PDd and malaria, haemolysis symptoms and 
blood transfusions (Table 2). No difference was observed 
between the G6PDd and normal groups in relation to 
the number of malaria episodes (Table 2). However, the 
number of haemolysis symptoms (anaemia OR 4.81, CI 
2.03–11.40, p value  <0.001; jaundice OR 7.13, CI 3.02–
16.85, p value <0.001; black urine OR 4.09, CI 1.75–9.56, 
p = 0.001), need for hospitalizations (OR 5.48, CI 1.27–
23.64, p  =  0.023) and blood transfusions (OR 3.33, CI 
1.17–9.45, p = 0.024) reported in the G6PDd group was 
higher than in the G6PD normal group (Table 2).
The G6PDd individuals were genotyped for 24 SNPs 
in the G6PD gene. These include the polymorphisms for 
the following variants: G6PD A(−), Mediterranean, Sea-
tle, Chatam, Santamaria, Betica-Selma, and other SNPs 
that were polymorphic in South America, according to 
the 1000 Genome data [14], and/or previously associated 
with protection to severe malaria [15–17]. According to 
the genotypes, 22 out of 23 G6PDd individuals had the 
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G6PD A(−) variant (376 A>G and 202 G>A mutations) 
(Additional file 3). One individual was G6PD A(+), which 
only includes the 376 A>G mutation. Almost all remain-
ing SNPs (n = 17) were monomorphic for the wild-type 
allele, including the Mediterranean, Seatle, Chatam, San-
tamaria, Betica-Selma variants. Three SNPs had a minor 
allele frequency (MAF) of 0.04 and were in complete 
linkage disequilibrium with the 202 G>A variant. One 
allele had a MAF of 0.31, with no differences in allele 
frequencies between ethnic groups. A similar frequency 
was reported in the 1000 Genomes project data for South 
America (MAF = 0.39) [14].
Table 1 Social and clinical characteristics of the study population
a Values are presented as mean ± standard deviation or absolute number (percentage); b combined Brazilian native, European and African ancestry. c Malaria 
episodes were reported as the infections presented during all life; For primaquine treatment the use was considered only for P. vivax infections; For the use of bed nets 
it was considered the habit of use and use the night before the interview; Individual protection includes the use of long-sleeved clothing, insect repellent to the body, 
aerosol and electric insecticides and use of screen on windows
Characteristicsa G6PD normal (N = 493) G6PD deficient (N = 23) Total (N = 516)
Age—years 36.4 ± 14.8 37.9 ± 12.3 36.5 ± 14.7
Ethnic group
 European descendant 70 (14.2) 3 (13.0) 73 (14.1)
 Afro- descendant 50 (10.1) 3 (13.0) 53 (10.3)
 Mestizob 368 (74.7) 17 (74.0) 385 (74.6)
 Others 5 (1.0) 0 5 (1.0)
Haemoglobin—g/dl 15.2 ± 1.3 15.0 ± 1.2 15.2 ± 1.3
ABO-Rh
 A+/A− 65 (13.2) 4 (17.4) 69 (13.4)
 B+/B− 17 (3.5) 1 (4.4) 18 (3.5)
 AB+/AB− 8 (1.6) 0 8 (1.6)
 O+/O− 117 (23.7) 5 (21.7) 122 (23.6)
History of  malariac
 Malaria episode 415 (84.2) 21 (91.3) 436 (84.5)
 Primaquine treatment 352 (71.4) 17 (73.9) 369 (71.5)
 Use of bed nets 358 (72.6) 19 (82.6) 377 (73.1)
 Use of insecticide-treated bed nets 244 (68.2) 17 (89.5) 261 (69.2)
 Indoor residual spraying 291 (59.0) 15 (65.2) 306 (59.3)
 Individual protection 152 (30.8) 8 (34.8) 160 (31.0)
Table 2 Previous clinical complications and malaria episodes
OR odds ratio
a Logistic regression model using clinical complications, need of hospitalization and blood transfusion
G6PD normal 
(N = 493)
G6PD deficient 
(N = 23)
Total  
(N = 516)
Crude OR  
[95% CI]
p value Adjusted OR  
[95%  CI]a
p value
Ethnicity 0.877 – –
 European-descendant 70 3 73 −
 Non-European 423 20 443 0.91 [0.26–3.13]
Previous episodes of malaria (episodes) 0.363 – –
 <3 258 11 269 1.50 [0.62–3.62]
 ≥3 156 10 166 –
Previous clinical complications
 Anemia 68 10 78 4.81 [2.03–11.40] <0.001 3.24 [1.26–8.27] 0.014
 Jaundice 76 13 89 7.13 [3.02–16.85] <0.001 4.02 [1.53–10.55] 0.005
 Black urine 119 13 132 4.09 [1.75–9.56] 0.001 1.77 [0.68–4.62] 0.241
Need of hospitalization 324 21 345 5.48 [1.27–23.64] 0.023 3.77 [0.83–17.16] 0.086
Need of blood transfusion 38 5 43 3.33 [1.17–9.45] 0.024 1.24 [0.38–4.03] 0.723
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Discussion
This is the first study to evaluate the prevalence of G6PD 
deficiency in the malaria-endemic region of Alto do 
Juruá, Acre state, located in the western Brazilian Ama-
zon. Approximately 95% of the malaria cases reported in 
Acre are found in the city of Cruzeiro do Sul and the sur-
rounding Alto do Juruá region, where this study was con-
ducted. This region is characterized by a high prevalence 
of Plasmodium vivax over Plasmodium falciparum infec-
tions with an Annual Parasitic Index above 200 cases per 
1000 inhabitants [18]. In this region in 2016, approxi-
mately 27,000 cases of P. vivax infections, 6240 of P. fal-
ciparum and 227 cases of co-infections were reported 
[18]. Individuals that are P. vivax-positive receive a rec-
ommended treatment of chloroquine and PQ. The evalu-
ation of G6PDd before PQ treatments is not part of the 
Brazilian National Programme for Malaria Control, 
therefore there is a risk for PQ to induce acute  haemo-
lytic anaemia in G6PDd individuals.
In this study, the prevalence of G6PDd was evalu-
ated in 516 male volunteers and a frequency of 4.5% 
was detected, which is similar to those reported else-
where in Brazil with an overall average of 5.2% (Table 3; 
Fig.  1). Some regions reported values higher than aver-
age (>8%), but study design differences have to be taken 
into consideration. These include differences in the study 
population, as in certain cases these involve hospital-
ized individuals or those with suspected G6PDd. The 
method used for G6PDd screening should also be taken 
in consideration.
Clinical history was explored in this study. Around 
82.6% of the G6PDd individuals have had at least one 
episode of anaemia, jaundice or black urine, compared to 
38.5% in G6PD normal individuals. Also, blood transfu-
sions occurred more frequently in G6PDd than normal 
individuals (21.7 and 7.7% respectively). Malaria episodes 
were reported in both groups at the same frequency, 
indicating that probably G6PDd does not protect against 
P. vivax infection. Other studies in Brazil have also 
reported an absence of association between G6PD phe-
notypes and the number of previous episodes of malaria 
(reviewed in [19]). In contrast, some studies found that 
G6PDd individuals were less likely to report the occur-
rence of malaria episodes [20, 21], and this could be due 
to: (i) the small number of subjects with G6PDd included 
in almost all studies, (ii) studies have relied on patients 
self-reporting the number of clinical episodes, and (iii) 
Plasmodium species is not determined and protection 
could be species-specific. Other factors such as other 
haemoglobinopathies could also be important confound-
ers. In Brazil, haemoglobin S was detected in 11.1% of the 
G6PDd individuals, and other regions in South America 
have reported similar values. In this study, it was not 
possible to investigate if G6PDd protects against malaria 
severity as previously reported [15–17, 22].
The prevalence of genetic variants associated with 
G6PDd were investigated, and 22 out of 23 individu-
als were detected with the G6PDd A(−) variant, and 
one individual with the A(+) variant. The prevalence of 
the G6PDd A(−) variant agrees with data reported in 
Brazil, where an average of 86% of individuals have the 
A(−) variant (Table 3). This variant has been detected in 
a Brazilian fatal primaquine-Induced haemolysis patient 
with P. vivax malaria [23]. Therefore, it is important to 
recognize that G6PD A(−), may result in a severe and 
life-threatening haemolysis on intake of PQ. The Medi-
terranean variant is the second most reported in Brazil 
[7], but it was not present in this population. Other South 
American countries have also reported similar frequen-
cies [7, 24].
The Brazilian population is quite heterogeneous, with 
a high degree of admixture from different ethnic origins. 
Besides the native Amerindians, Brazilians descend from 
African populations from diverse regions and migrants 
from Europe (Portugal, Italy, Spain, Germany) and Asia 
(Japan). The frequency of G6PDd among ethnic groups 
was investigated and an increase of G6PDd was found 
in Afro-descendants (5.6%) but this difference was not 
significant when compared to European descendants 
(4.1%) and those of combined Mestizo ancestry (4.4%) 
(p  =  0.918). The data from this and other studies sug-
gest that the Brazilian population is quite homogeneous 
regarding G6PDd, regardless of the ethnic groups.
This study is one of few that investigated G6PDd in 
an area endemic for malaria in Brazil. Fewer than one 
in three studies were performed in malaria-affected 
areas and focused on Manaus, Acre and Rondônia, with 
an absence of information available in other malaria-
endemic areas. In Brazil, PQ is used in P. vivax infected 
patients to prevent malaria relapse episodes, but in the 
absence of informative G6PDd screening. The complete 
treatment of P. vivax malaria advised by the Brazilian 
Ministry of Health includes a 3 day dose of chloroquine 
(25 mg/kilo of body weight) and a 7 day (0.5 mg/kg) or 
14  day (0.25  mg/kg) scheme of PQ treatment. A short 
7  day scheme doubling the PQ dose in order to avoid 
patients low adhesion to the prolonged treatment is also 
accepted.
In the Juruá Valley region, the data suggest that one in 
every 23 male individuals could be G6PDd and, therefore, 
at risk of haemolysis after PQ treatment. In the Brazilian 
Amazon several reports have associated G6PDd with a 
considerably higher risk of haemolysis in patients using 
PQ, and lethal cases have also been reported (reviewed 
in [19]). G6PDd screening should be considered by the 
Malaria Control programmes before PQ administration. 
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Moreover, two studies have shown that the use of PQ in 
G6PDd men represents a heavy burden on the Brazilian 
public health service, and G6PDd detection would result 
in better use of public resources [23, 25].
Conclusion
In this study, the prevalence of G6PDd was evaluated in a 
malaria-endemic region in the Western Amazon region, 
and detected a frequency of 4.5%. The G6PDd A(−) vari-
ant was responsible for almost all G6PDd (22/23 indi-
viduals). Because this region is endemic for P. vivax, PQ 
treatment is routinely used to prevent relapses from the 
dormant hypnozoites in the liver. Consequently, one in 
each 23 males could be G6PDd and at risk to develop 
haemolytic anaemia upon PQ administration. In order 
to decide the importance of routine G6PDd screening, 
particularly if complete treatment of patients with vivax 
malaria is needed to accelerate elimination of the dis-
ease, it is important to consider the cost and feasibility of 
screening and the risk of severe haemolytic response at 
different levels of G6PDd.
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